INTRODUCTION
The vast majority of pancreatic tumors are primary, and metastatic tumors of the pancreas are rare, although direct invasion from advanced cancers in neighboring organs is sometimes observed. Metastatic tumors in autopsy series have been reported in from 3% to 11% [1, 2] . Furthermore, the majority of patients with pancreatic metastasis have widespread disease [3] . Metastatic disease to the pancreas has been only infrequently diagnosed in living patients.
Furthermore, although surgical resection of metastatic lesions to the liver, lungs, and brain have been shown to improve survival and quality of life, the optimal management of pancreatic metastasis has not been clearly delineated. However, over the past few years, morbidity and mortality improvements after surgical resection of the pancreas have enabled patients with metastatic disease to be treated with radical intent [4, 5] . Here, we report our experiences of eleven patients who underwent pancreatic resection for metastasis to the pancreas. 
RESULTS
Median patient age was 54 years (range, 35 to 75 years), and 8 men and 3 women were included in the study. Of these 11 patients, 7 patients had been previously treated for renal cell carcinoma (RCC), 2 for a carcinoid tumor, 1
for rectal adenocarcinoma, and 1 for leiomyosarcoma of the lower extremity. Details of clinical findings are summarized in Table 1 .
The median time between primary surgery and a diagnosis of pancreatic metastasis was 51 months (range, 14 to 180 months). Nine patients were asymptomatic and metastatic lesions were discovered during follow-up. The Three patients showed evidence of concurrent ex-thesurgery.or.kr 
DISCUSSION
Metastatic lesions to the pancreas are uncommon, and account for less than 2% of all pancreatic malignancies.
The tumors that metastasize most frequently to the pancreas are renal cell carcinoma, melanomas, sarcoma, and colon, lung, and breast cancer [1, 2, 6] . Although pancreatic metastasis is rare, high volume centers will encounter patients with resectable metastatic disease. Reddy et al. [7] reported on 49 patients that underwent pancreatic re- [7] reported that 45 of 49 patients (92%) had symptoms of abdominal pain, jaundice, weight loss, whereas
another study reported that 6 of 13 patients (46%) were asymptomatic [2] . In our series, 9 of 11 patients (82%) were asymptomatic.
The preoperative differential diagnosis between a primary pancreatic neoplasm and a metastatic tumor may be problematic. Palmowski et al. [9] showed that unlike pancreatic adenocarcinoma, secondary pancreatic cancers usually show arterial phase enhancement on contrast-enhanced CT scans. Furthermore, unlike pancreatic adenocarcinoma, metastatic pancreatic lesions from RCC, colorectal cancer, and breast cancer tend to be rim-enhanced. In the present study, 9 metastatic lesions from 7 RCC and 2 carcinoid tumor were rim-enhanced or heterogeneously enhanced, whereas the other 2 lesions from rectal cancer and leiomyosarcoma were not. Furthermore, in order to avoid major surgery, accurate preoperative staging must be done in patients with widespread disease [3, 4, 10, 11] , and 18-FDG-PET has proven to be useful in this context [5, 12] . Our patient with a metastatic carcinoid tumor in the mediastinum and pancreas was found to have two other lesions by 18-FDG-PET, which were not detected by CT, but which were finally confirmed by endoscopic ultrasonography. Percutaneous and endoscopic fine-needle biopsies may help establish a pathological diagnosis when a metastatic tumor is not amenable to surgery, but may be treated with chemotherapy.
The time between diagnosis of primary cancer and the detection of pancreatic metastasis varies widely, and in particular, renal cell cancers are associated with a prolonged disease-free interval [4, 6, 13] . In the present study, Originally, radical nephrectomy was the gold standard for RCC without metastasis. However, the increase in small renal tumors incidentally found at earlier stages has lead to organ preserving surgery which been more frequently preferred to radical nephrectomy for tumors less than 4 cm in diameter and limited to the kidney. For smaller tumors (＜ 2 cm in diameter), simple enucleation, dissecting around the pseudocapsule of the tumor, can be applied [15] . Similarly, we assumed that the biology of primary tumor would be same as if metastasis is solitary and the size is small. Therefore, metastatic RCC to the pancreas less than 2 cm in diameter that was not close to a main pancreatic duct can be a good indication for organ preserving pancreatectomy such as enucleation. In our series, 2 patients with metastatic RCC smaller than 2 cm underwent enucleation and has been disease-free status at 7, 69 months postoperatively. However, further studies in organ preserving pancreatectomy for small metastatic RCC are necessary.
Since our study has the limitation of small sample size, heterogeneity of the primary tumor, some combination of adjuvant therapy and retrospective design, it might be difficult that surgical resection of pancreatic metastases would provide survival benefit. Additional follow up of our cohort and more experience of surgical resection for pancreatic metastasis would clarify these limits.
In conclusion, patients with a low surgical risk should be considered for pancreatic metastasectomy if curative resection is possible. Careful selection of patients undergoing pancreatic resection for metastatic disease should be based on the primary cancer type which is associated with survival benefit after metastasectomy.
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